Adjuvant intravesical immunotherapy is recognized as an effective treatment option for various urological cancer types. It plays a significant role in reducing the risk of recurrence, particularly in high-risk non-muscle-invasive bladder cancer cases. This treatment method is commonly utilized to diminish tumor residues following transurethral resection and prevent disease progression. Among the most frequently employed agents are BCG (Bacillus Calmette-Guérin) and interferon. Adjuvant intravesical immunotherapy is typically administered alongside or following other treatment modalities to minimize local and systemic side effects. Due to its low invasiveness and relatively high efficacy, this treatment holds a crucial place in the management of non-muscle-invasive bladder cancer.
This section contains information about the symptoms and diagnostic stages of bladder cancer. The approach to hematuria, the most common presenting symptom in bladder cancer, is also emphasized. The effectiveness of screening in asymptomatic patients is still debated. Traditional methods continue to be reliably used in the diagnosis of bladder cancer. However, new imaging methods and markers, proven to enhance diagnostic success, are expected to be routinely used in diagnosis and follow-up.
LHRH agonists and antagonists are crucial in managing metastatic prostate cancer. These agents target the hypothalamus and pituitary gland, suppressing the production of luteinizing hormone-releasing hormone (LHRH). By doing so, they reduce testosterone levels, a key driver of prostate cancer growth. LHRH agonists like leuprolide and goserelin are widely used as first-line treatments, while newer LHRH antagonists such as degarelix offer alternative options. Both classes of drugs have demonstrated efficacy in delaying disease progression, alleviating symptoms, and improving quality of life in metastatic prostate cancer patients. Treatment selection often considers factors such as patient preferences, side effect profiles, and cost-effectiveness, highlighting the importance of individualized care in optimizing outcomes for patients with metastatic prostate cancer.
1 January 2026 in SiSli Etfal Hastanesi Tip Bulteni / The Medical Bulletin of Sisli Hospital
To evaluate the impact of percutaneous nephrostomy (PN) on family burden, health-related quality of life (HRQoL), depressive symptoms, and pain, and to identify predictors of postoperative change. In this prospective study, 119 patients undergoing PN for obstructive uropathy were assessed before and after PN using the Visual Analog Scale (VAS), Beck Depression Inventory (BDI), EQ-5D-3L sum score, and Family Reported Outcome Measure-16 (FROM-16). Pre- and post-procedure differences were analyzed using the Wilcoxon signed-rank test, and multivariable linear regression was used to identify predictors of change (p<0.05). The mean age was 61.7 years, and 64.7% of the patients were male. Malignancy was the most common etiology, followed by stone disease and benign strictures. All outcomes deteriorated after PN: FROM-16 increased from 7.39 to 15.87, EQ-5D-3L sum score from 7.45 to 13.71, BDI from 12.97 to 17.92, and VAS from 1.22 to 5.23 (all p<0.001). Malignancy, ureteral stricture, and infection were associated with smaller increases in family burden. Spousal caregiving was associated with greater HRQoL deterioration (p=0.020), whereas infection predicted less worsening. Older age was associated with greater increases in BDI, while longer marriage duration and unemployment were associated with smaller BDI changes (p<0.05). Pain worsening was less pronounced in male patients and those with higher education levels (p<0.05). Although PN relieves obstruction, it is associated with significant deterioration in psychosocial outcomes. Psychosocial screening and caregiver support should be integrated into PN care pathways to protect patient-centered outcomes.